Let's talk
Contact us
BioDuro- Shanghai Facility
September 2012

BioDuro Opens State-of-the-Art Discovery Lab in Shanghai

Discovery lab is strategically located for collaboration with local and multinational non-governmental organizations, pharmaceutical and biotech companies

BioDuro, A PPD® Company, unveiled its new state-of-the-art laboratory in Shanghai during a grand opening ceremony on 6 Sept. The facility is located in the Waigaoqiao Free Trade Zone in close proximity to local and multinational pharmaceutical and biotechnology companies and non-governmental organizations (NGOs) in Shanghai and expands BioDuro’s capability to provide world-class drug discovery services to these companies.

Government officials from the Shanghai Free Trade Zone, the Administration Committee of the Waigaoqiao Free Trade Zone, the Pudong New District and the Science and Technology Commission of Shanghai attended the ceremony, along with a number of BioDuro’s partner clients in the Shanghai area, the company’s staff and other invited guests.

During her remarks, Jasmine Cui, general manager and chief scientific officer of BioDuro, noted that the opening of the Shanghai facility is an important component of PPD’s local and global strategies.

The vision for our lab is to play a key role in helping establish an innovative research and development center in Shanghai,” Jasmine said. “Our goal is to not only serve multinational biopharmaceutical companies, but also to collaborate with Chinese companies and contribute to the development of the local pharmaceutical industry and the future of the Shanghai Free Trade Zone.

Lee Babiss, PPD chief scientific officer and executive vice president of discovery innovation, said the new lab also is an important part of the company’s efforts to provide a wide range of integrated services, with BioDuro focusing on discovery and pre-clinical services.

This lab enables us to meet the business needs of our clients more effectively by streamlining the discovery and development process and by continuing to enhance continuity and smooth transitions throughout the stages of drug development,” Lee said. “Our innovative solutions create value for clients, enabling them to get to the next stage of development in a rapid and high-quality manner.

Back to articles